Home / Venues / Medicine and clinical research / The Lancet Oncology
The Lancet Oncology
Medicine and clinical research
Among the 50 medicine and clinical research journals in this index it has the 12th highest h-index and the 7th highest two-year mean citedness. Both are explained under how venues are ranked.
Listed article processing charge: about $7 280.
Where its authors come from
Share of the 1 730 papers since 2023 with at least one author in each country.
| Country | Share of papers |
|---|---|
| United States | 32% |
| United Kingdom | 20% |
| France | 14% |
| Netherlands | 12% |
| Italy | 12% |
What it publishes
Mix of article types:
| Type | Share |
|---|---|
| Research articles | 91% |
| Letters | 5% |
Main subject areas of those papers:
| Subject area | Share of papers |
|---|---|
| Global Cancer Incidence and Screening | 6% |
| Advances in Oncology and Radiotherapy | 4% |
| Breast Cancer Treatment Studies | 3% |
| Cancer Immunotherapy and Biomarkers | 2% |
| Head and Neck Cancer Studies | 2% |
| Pharmaceutical Economics and Policy | 2% |
Most cited papers since 2023
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023, 689 citations)
- Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study (2023, 581 citations)
- Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023, 461 citations)
- Global variations in lung cancer incidence by histological subtype in 2020: a population-based study (2023, 438 citations)
- Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study (2023, 388 citations)
Official rankings
Many evaluations use a national or commercial list rather than raw citation counts. We don't reproduce those lists here; check the journal on each one directly (search for ISSN 1470-2045):
- Scimago (SJR and quartile): what quartiles mean
- Norwegian register (level 1 or 2): national lists explained
- Finnish Publication Forum (JUFO level 0 to 3)
Similar journals
- JNCI Journal of the National Cancer Institute
- Journal of Clinical Oncology
- Journal of Clinical Investigation
- Nature Reviews Cancer
- Statistics in Medicine
- BMC Medical Research Methodology
Submitting to The Lancet Oncology? DeskReady checks your final PDF against itself before you do: numbers against the tables, claims against the results, figures against their captions, every reference against the databases. Each finding is highlighted on your own page. The first check is free.
Check your paperOnly the reference list? Check it free, no account needed.
Citation measures from open bibliographic data, retrieved 2026-10-17; values differ from Scopus or Web of Science. Data sources. DeskReady is not affiliated with this journal.